Top Markets
Coin of the day
Annovis Bio, Inc. Annovis Bio, Inc.

Annovis Bio, Inc.

ANVS
株式のランク #23205
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on... Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
株価
$1.81
最終同期: 2026-08-21
時価総額
$77.00M
変化(1日)
1.30%
変化(1年)
-23.63%
US
取引 Annovis Bio, Inc. (ANVS)

カテゴリー

Annovis Bio, Inc.(ANVS)の株式分割履歴
Annovis Bio, Inc.株(シンボル:ANVS)は合計で0回の株式分割を実施しました。
最新の株式分割はAug 22, 2026に行われました。
Aug 22, 2026より前に購入されたANVS株は、現在0ANVS株に相当します。
株式分割一覧
株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割
企業 株式分割の回数 累積分割比率
1 x2
US
0 -
NL
0 -
US
1 x3
AU
0 -
CH